AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Kintsugi 150mg Injection

Prescription Icon
Prescription Required

Marketer

Mankind Pharma Ltd

Salt Composition

Trastuzumab (150mg)

Overview Kintsugi 150mg Injection

Herceptin-equivalent Kintsugi 150mg injection combats breast and gastric cancers by targeting and eliminating HER2-positive cells. Administered intravenously by healthcare professionals, dosage and frequency are personalized by your physician based on your condition and may vary. Strict adherence to prescribed regimens is crucial; deviations can lead to severe adverse reactions. Therapeutic effects may be gradual, taking weeks or months to manifest; discontinuation should only occur under medical supervision. Common side effects include nausea, headaches, skin rashes, sleep disturbances, and increased infection risk. Kintsugi may suppress blood cell production, necessitating regular blood tests monitoring complete blood count, hepatic function, cardiac status, and uric acid levels. Report shortness of breath, cough, chills, or limb swelling immediately. Drug interactions are possible; disclose all medications to your healthcare provider. Pregnancy and breastfeeding are contraindications; reliable contraception is essential for both partners throughout treatment.

Uses of Kintsugi 150mg Injection

Cancers affecting the breast and stomach.

Major Benefits of Kintsugi 150mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Kintsugi 150mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Kintsugi 150mg Injection:

The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

How Kintsugi 150mg Injection works:

Kintsugi, a 150mg injectable monoclonal antibody (IgG1), targets HER2 receptors—human epidermal growth factor receptor 2 proteins—responsible for excessive cell growth in breast and gastric cancers. Its mechanism involves HER2 inhibition, leading to cancer cell destruction and disruption of downstream signaling cascades implicated in carcinogenesis.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Kintsugi 150mg Injection and alcohol may result in increased sleepiness.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Kintsugi 150mg Injection during pregnancy is contraindicated due to established risks to fetal development. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administering Kintsugi 150mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

Driving ability may be impacted by Kintsugi 150mg Injection; however, this effect is currently undetermined. Refrain from operating a vehicle if experiencing symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

Kintsugi 150mg Injection appears safe for use in individuals with kidney impairment. Preliminary findings indicate dose modification may be unnecessary. Physician consultation is advised.

LiverLiverCONSULT YOUR DOCTOR

Data regarding the administration of Kintsugi 150mg Injection to individuals with hepatic impairment is scarce. Physician consultation is recommended.

What if you forget to take Kintsugi 150mg Injection :

Omit a Kintsugi 150mg Injection? Seek your physician's advice.

Facts to Know About Kintsugi 150mg Injection

LabelValue
Chemical Type Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Action Class Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Kintsugi 150mg Injection

Kintsugi 150mg Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bleeding or bruising. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea, vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Seek immediate medical attention if any of these symptoms occur.
Women of childbearing age must use effective contraception throughout Kintsugi 150mg Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Early-stage breast cancer patients should receive Kintsugi 150mg Injection for one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Kintsugi 150mg Injection does not require fasting beforehand. Administration must be supervised by a physician experienced in administering cancer chemotherapy, and should only be performed by a healthcare professional.
Kintsugi 150mg Injection is available in two formulations: intravenous (IV) infusion and subcutaneous injection. Always verify the product label to ensure correct administration. The IV formulation is for intravenous infusion only and must not be given subcutaneously. Your doctor may change your treatment between the IV and subcutaneous formulations as needed.
Kintsugi 150mg Injection, a monoclonal antibody targeting the HER2 protein, is ineffective in patients with HER2-negative cancer. Its mechanism involves binding to HER2, found abundantly on the surface of some cancer cells, thus inhibiting their growth and spread. Consequently, this injection is only beneficial for patients with HER2-positive cancers.
Using Kintsugi 150mg Injection with anthracycline cancer drugs (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and throughout treatment.
Cardiac evaluations should begin at treatment initiation, continue every three months throughout treatment, and then every six months post-treatment for up to 24 months following the final Kintsugi 150mg Injection. Patients with pre-existing cardiac conditions require evaluations every twelve weeks.
Kintsugi 150mg Injection
6,320
MRP 7,700
17% off